


## About Immunocore

Immunocore is the world's leading T cell receptor (TCR) biotechnology company, developing first-in-class biologic therapies based on proprietary TCR technology. This is a novel class of TCR-based bi-functional biologic drugs with the potential to treat multiple major indications including cancer, infectious diseases and autoimmune diseases. The scientific expertise at Immunocore spans the entire process of drug development, from the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, to preclinical and clinical assessment.

Immunocore is headquartered near Oxford, UK with offices near Philadelphia, US and currently employs >370 employees. The Company is privately held by a broad international and private investor base. Immunocore's wholly-owned lead programme, IMCgp100, is in pivotal monotherapy trials in the area of immuno-oncology for the treatment of metastatic uveal melanoma. Immunocore is also conducting a combination trial with AstraZeneca for the treatment of cutaneous melanoma, combining IMCgp100 with checkpoint inhibitors Imfinzi and tremelimumab.


## ImmTAC™ Platform

ImmTAC molecules (Immune mobilising monoclonal TCRs Against Cancer) comprise a soluble engineered TCR fused to an immune activating effector function.



## ImmTAC Technology

ImmTAC molecules function to re-direct T cells to target cells (e.g. cancer cells) that present a target peptide on the surface of major histocompatibility complexes (MHC).



## Focus

Immunocore is developing and commercialising TCR-based therapeutics for diseases with a high unmet medical need.

## Management

**Jonathan Knowles**  
Chairman

**Eliot Forster**  
Chief Executive Officer

**Paul Fry**  
Chief Financial Officer

**Bent Jakobsen**  
Chief Scientific Officer

**Eva-Lotta Allan**  
Chief Business Officer

**Christina Coughlin**  
Chief Medical Officer

**James Sandy**  
Chief Development Officer

**Kevin Pojasek**  
Director of Corporate Strategy

## Contact Us

**Immunocore Ltd**  
101 Park Drive, Milton Park  
Abingdon  
Oxfordshire  
OX14 4RY  
UK  
T: +44(0)1235 438600

**Immunocore LLC**  
Six Tower Bridge, Suite 540  
181 Washington Street  
Conshohocken, PA 19428  
USA  
T: +1 (484) 534-5261

E: [info@immunocore.com](mailto:info@immunocore.com)

[www.immunocore.com](http://www.immunocore.com)

**Lead Programme: IMCgp100**

Immunocore's lead programme, IMCgp100, targets the melanoma associated antigen gp100. IMCgp100 is in a pivotal monotherapy trial for patients with metastatic uveal melanoma, an aggressive form of melanoma with a poor prognosis and resistant to checkpoint inhibitors and other novel therapies. IMCgp100 was granted orphan drug designation by the US Food and Drug Administration in 2016.

**Expanding the Platform**

Immunocore's TCR technology has a broad applicability to a wide range of intracellular targets and disease indications including solid tumours, and can expand into infectious diseases (ID) and autoimmune diseases (AI).



Building on ImmTAC technology, TCR specificity to viral or bacterial targets can be engineered and new effector functions can be developed to deliver novel small protein molecules to address diverse disease indications with high unmet clinical need.

**Infectious Diseases**

**ImmTAV/B™**

(Immune mobilising monoclonal TCR against viruses/bacteria)

TCR specificity is engineered to recognise and kill virally or bacterially infected cells. Initial target indications are HIV, HBV and Tuberculosis.



**Autoimmune Diseases**

**ImmTAAI™**

(Immune mobilising monoclonal TCR against autoimmune diseases)

New effector functions are in development to activate immunosuppressive signalling pathways.

**Pipeline**

Immunocore has a rapidly expanding pipeline of wholly-owned programmes complemented by strategic partnerships.

Product	Indication	Stage of Development				Owner / Collaborator
		ImmTAC generation	IND-enabling	Phase I/II	Pivotal	
IMCgp100	Uveal melanoma	█	█	█	█	IMMUNOCORE
IMCgp100 checkpoint combinations	Cutaneous melanoma	█	█	█	█	IMMUNOCORE AstraZeneca
IMCgp100 kinase inhibitor combination	Uveal melanoma	█	█	█	█	IMMUNOCORE Lilly
GSK #1	NSCLC/ Bladder cancer/ Synovial sarcoma	█	█	█	█	gsk
IMC-C103C	Lung/ Head & Neck/ Oesophageal	█	█	█	█	IMMUNOCORE
IMC-D104C	Lung/ Ovarian/ Breast/ Endometrial	█	█	█	█	IMMUNOCORE
Additional oncology programmes	Various	█	█	█	█	IMMUNOCORE
Partnered oncology programmes	Various	█	█	█	█	Genentech gsk Lilly AstraZeneca
Infectious disease programmes	Various	█	█	█	█	IMMUNOCORE
Autoimmune programmes	Various	█	█	█	█	IMMUNOCORE

**Partnerships**

Across the oncology pipeline, Immunocore has collaborations with Genentech, GlaxoSmithKline, AstraZeneca and Lilly targeting a range of solid tumours.

**Discovery collaborations:**

Immunocore has entered into multi-target collaborations with AstraZeneca, Genentech and GSK, with up to \$20M upfront fees per programme, in addition to significant milestones and royalties.

**Co-discovery and co-development collaboration:**

Immunocore has entered into a multi-target collaboration with Lilly, with a \$15M upfront fee per programme plus a \$10M pre-clinical opt-in fee, with the option to co-develop and co-promote.

**IMCgp100 combination trials with AstraZeneca:**

Immunocore is conducting a clinical combination study with IMCgp100 combined with checkpoint inhibitors Imfinzi (durvalumab) and tremelimumab in patients with metastatic cutaneous melanoma who are refractory to anti-PD-1 therapies.

The Bill & Melinda Gates Foundation has invested up to \$40M to support the development of ImmTAV and ImmTAB therapeutics for infectious diseases that pose a global health challenge.

